Cystic Fibrosis (CF) is an autosomal recessive disorder caused by mutations in the Cystic Fibrosis Transmembrane Regulator (CFTR) gene, affecting the respiratory and gastrointestinal systems. With 40,000 adults and children in the US and 105,000 worldwide, the disease has a sharply increasing incidence and survival rate (Rafeeq and Murad, 2017). The discovery of the CFTR gene in 1989 provided hope for the scientific and medical sectors, leading to the identification of over 2000 different mutations. This has improved diagnosis and care for CF patients and their families and opened the door for the creation of treatments specific to specific mutations. CF damages multiple organs, leading to progressive lung damage and mortality. Advancements in healthcare and treatments have raised the median age of death for CF patients to the early fifties. Recent advances in pharmaceutical interventions, particularly CFTR modulators, allow for targeting the genetic root of CF mutations, potentially rescuing mutant CFTR function and improving the quality of life for CF patients (Suiet al., 2022). This review is organized into the following sections. CFTR Genetic lesions: Discusses the spectrum of genetic mutations, including missense, nonsense and splicing defects, with a focus on their molecular mechanisms. Phenotypic Expressions of Cystic Fibrosis: Explores the correlation between specific CFTR mutations and the resulting clinical manifestations, emphasizing pulmonary, gastrointestinal and reproductive health. Current Therapeutic Approaches: Summarizes established treatment strategies, including symptomatic management and CFTR modulators. Emerging Therapies: Highlights recent advancements in gene therapy, mRNA therapy and small-molecule correctors targeting underlying genetic defects. Challenges and Future Directions: Discuss existing gaps in CF management and research and outline potential strategies for overcoming these barriers. Conclusion: Provides a concise summary of findings and their implications for clinical practice and research.

Cystic Fibrosis (CF) is a genetic disorder characterized by the presence of two copies of CFTR-mutated genes from both parents. The CFTR gene is located on chromosome 7 and is composed of 27 coding exons. Over 2,000 distinct CFTR gene variants have been reported, with 432 found by the Clinical and Functional Translation of CFTR. Some variants have shown disease liability and clinical consequences. The CFTR protein is a 1,480-amino acid protein located on the apical membrane of epithelial cells. It is composed of five distinct domains: Transmembrane Domains (TMD1 and TMD2), Nucleotide-Binding Domains (NBD1 and NBD2) and a Regulatory Domain (RD). The CFTR protein’s biosynthesis and post-translational folding are significantly influenced by the TMDs. The CFTR protein’s complex structure allows chloride ions to exit epithelial cells and it is expressed in various organs such as the lungs, upper respiratory tract, pancreas, liver, gallbladder, intestines and sweat (Pereira, Ribeiro, Ribeiro, Bertuzzo, and Marson, 2019; Liuet al., 2019; Zhang, Liu, and Chen, 2017).

Class I CFTR mutations result in a shortened, non-functional CFTR protein, leading to recurrent infections, inflammation and lung damage. These mutations are the most severe type, accounting for 5-10% of cases of cystic fibrosis. Notable nonsense mutations include G542X, W1282X and R553X. Class II mutations cause the CFTR protein to misfold, preventing it from reaching the cell membrane. The most common mutation, F508del, causes the phenylalanine at position 508 of the CFTR protein to be deleted, causing the protein to misfold and disrupt the three-dimensional structure. This leads to impaired transport of bicarbonate and chloride across epithelial cell membranes, causing persistent bacterial infections and respiratory issues. Class III mutations result in a protein that reaches the cell surface but fails to react appropriately to cellular cues regulating channel gating. G551D is a well-known Class III mutation, where aspartic acid is substituted for glycine at position 551, resulting in a more closed state and lower channel open probability. These mutations can lead to serious respiratory issues and a lack of proper cellular function (Stanke and Tümmler, 2016).

The genotype-phenotype correlation in Cystic Fibrosis (CF) is the link between specific CFTR mutations and the disease’s clinical symptoms. CF affects various organ systems, including the lungs, pancreas, liver, intestines and reproductive organs. The disease’s severity is influenced by specific CFTR mutations and environmental variables. Respiratory manifestations vary based on mutation type, with CF causing thick mucus production, chronic infections and lung inflammation (López-Valdezet al., 2021) as depicted in Figure 1. Chronic infections and inflammation are caused by genetic mutations, mucus accumulation and structural damage to the lungs. Infections from various bacteria are common in CF patients (Turcios, 2020).

The quality of life of patients with cystic fibrosis can be greatly affected by the severe Gastrointestinal (GI) symptoms of the disease. GI symptoms that are important in cystic fibrosis are listed in Table 1.

Cystic Fibrosis (CF) is a prevalent condition causing reproductive issues, particularly male infertility. The endocrine system can also be affected, leading to diabetes related to CFRD. The quality of life is significantly impacted by these systemic signs, necessitating comprehensive, multidisciplinary care. CF-affected females may experience thick cervical mucus, chronic lung infections, low nutritional status and diabetes. Advances in CF care have improved fertility and pregnancy outcomes. CF patients also face major metabolic and endocrine system disruptions, including insulin resistance, decreased insulin synthesis, poor nutritional status, stunted growth, vitamin D insufficiency, abnormal calcium metabolism and bone damage. Comprehensive management and regular monitoring are essential for improving the quality of life and long-term results (Jainet al., 2021).

Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) modulators are drugs that target the faulty CFTR protein to cure the underlying cause of Cystic Fibrosis (CF). The CFTR protein controls the flow of water and salt into and out of cells, particularly in the digestive and pulmonary systems. A accumulation of thick, sticky mucus caused by a defective CFTR protein can cause digestive and respiratory issues (Ticeet al., 2021).

CFTR potentiators, which improve the CFTR protein’s cell surface function, have become a major focus of scientific research. These medications aid in the increased opening of CFTR channels, facilitating the more efficient passage of chloride ions. Clinically used CFTR potentiators include Ivacaftor (Kalydeco), which has proven effective in restoring CFTR channel activity (Csanády, Vergani, and Gadsby, 2019). Ivacaftor was the first CFTR modulator licensed by the U.S. Food and Drug Administration (FDA) in 2012 for the treatment of cystic fibrosis. Clinical trials have consistently shown that ivacaftor leads to significant improvements in lung function, reduced pulmonary exacerbations, weight gain, enhanced quality of life and fewer respiratory symptoms (Choet al., 2019). Long-term studies confirm that ivacaftor provides sustained benefits, including prolonged improvements in lung function and lower rates of lung infections and hospitalizations over several years of use. Ivacaftor has revolutionized cystic fibrosis treatment for individuals with responsive mutations, offering significant clinical benefits and enhanced quality of life (Duckerset al., 2021).

CFTR correctors are pharmacological agents that improve the trafficking, folding and processing of the CFTR protein to the cell surface. They address mutations like F508del, preventing misfolding and proteolytic degradation. These medications increase functional protein at the cell surface and work synergistically with potentiators to enhance protein function. Lumacaftor, a drug approved by the FDA in 2015, is a combination therapy that improves the management of cystic fibrosis, particularly in patients with the F508del mutation in the CFTR gene (Cheng, Alexiou, and Rubenstein, 2019). It corrects misfolding of the CFTR protein, enhancing its flow to the cell surface and facilitating its movement to the cell surface. The combination therapy has shown significant improvements in lung function, pulmonary exacerbations and quality of life for patients with two copies of the F508del mutation. However, it also has potential side effects, including liver-related events, respiratory symptoms, elevated blood pressure, hypersensitivity reactions and drug interactions. Tezacaftor, a drug similar to lumacaftor, assists in the correct folding and trafficking of the CFTR protein to the cell surface. When paired with ivacaftor, tezacaftor is highly effective in treating cystic fibrosis patients with specific mutations, increasing lung function, decreasing pulmonary exacerbations and improving quality of life. The EVOLVE and EXPAND trials confirmed the drug combination’s effectiveness and safety, showing notable improvements for both heterozygous and homozygous F508del patients (Kuk and Taylor-Cousar, 2015).

CFTR amplifiers and readthrough agents are two pharmacological approaches aimed at improving CFTR function in Cystic Fibrosis (CF) patients. CFTR amplifiers increase the production of CFTR protein or enhance its stability at the cell surface, without directly correcting folding defects or enhancing channel gating (Dukovskiet al., 2020). They work by boosting transcription or translation of CFTR mRNA, leading to increased CFTR protein production. VX-659, developed by Vertex Pharmaceuticals, is part of a combination therapy with tezacaftor and ivacaftor, marketed under the brand Trikafta. Readthrough agents overcome premature stop codons in the CFTR gene, enabling the production of a full-length, functional CFTR protein. Ataluren targets premature stop codons to facilitate full-length CFTR protein production (Dukovskiet al., 2020).

Triple therapy, a combination of ivacaftor/tezacaftor/elexacaftor, is a treatment for Cystic Fibrosis (CF) patients with at least one Phe508del mutation in the CFTR gene. This treatment improves pulmonary function, reduces exacerbations and enhances quality of life. The CFTR modulators, such as elexacaftor, tezacaftor and ivacaftor, have shown significant clinical outcomes, including improved lung function, decreased exacerbations, improved quality of life and improved nutritional status (Konstanet al., 2020).

CRISPR is a gene-editing technology developed by Streptococcus pyogenes that integrates foreign DNA into their genome. This technology involves the use of scaffolding trans-activating short RNAs (tracrRNAs) to interact with a nuclease protein, Cas9 (Konstanet al., 2020). However, the implementation of CRISPR-Cas9 technology is hampered by the unique physiology of Cystic Fibrosis (CF) lung. The efficiency of CRISPR-Cas9 depends on the target cell type, delivery method and genetic alterations site. Various editing methods, including prime, base and HITI editing, have their own advantages and drawbacks. HITI allows for precise insertion of genes without causing double-strand breaks, while base editing allows for direct conversion of DNA base pairs without double-strand breaks (Graham and Hart, 2021). Prime editing allows for precise genome editing without double-strand breaks, but efficiency may vary depending on the complexity of the edit and the target genomic region. Various techniques, such as electrophoration, nanoparticles and RNA-mediated delivery, have been used to deliver CRISPR-Cas9 to various cell types (Wei, Cheng, Min, Olson, and Siegwart, 2020).

Adenovirus (Ad) vectors are effective for gene delivery in cystic fibrosis patients, but require repeated administrations due to pro-inflammatory effects. Adeno-Associated Virus (AAV) vectors have longer in vivo persistence and potential for restoring CFTR function with minimal toxicity (Wang, Gessler, Zhan, Gallagher, and Gao, 2024). Non-viral vectors, which can carry larger DNA fragments, have lower efficacy and require repeated treatments due to transient gene expression, making them less effective for long-term lung function restoration in cystic fibrosis (Leeet al., 2021).

Cystic Fibrosis (CF) is a lung disease that requires a multifaceted approach to manage. Anti-inflammatory agents, such as corticosteroids and NSAIDs, are used to reduce chronic inflammation in the lungs, which contributes to lung damage and disease progression. However, their use is limited by adverse effects and adsorption. Research into other anti-inflammatory strategies, such as specific antibodies and neutrophil-targeted therapies, is ongoing (Chmiel and Konstan, 2005). Mucociliary clearance enhancers help clear thick mucus from the lungs, improving respiratory function and reducing infection risk. Antimicrobial treatments, such as inhaled and systemic antibiotics, are crucial in managing CF by targeting chronic and recurrent respiratory infections. Long-term antibiotic therapy is often necessary to address antibiotic resistance and maintain lung function (Manos, 2021).

Figure 1:
Lung parenchymal changes in CF. Adapted from “Cystic Fibrosis Airways”, by BioRender.com (2025). Retrieved from Retrieved from https://app.biorender.com/biorender-templates.

Ongoing clinical trials are essential for evaluating the effectiveness of these personalized therapies and understanding their long-term impacts on CF patients. Research into new models and delivery methods is also critical for advancing personalized medicine in CF.

A Phase 2B clinical trial evaluated the efficacy of a gene therapy for Cystic Fibrosis (CF) by delivering the therapy to patients’ airways over 12 months. This randomized, double-blind, placebo-controlled study found that the treatment significantly improved lung function. The main endpoint showed a 3.7% improvement, with a 95% confidence interval ranging from 0.1% to 7.3% and the result was statistically significant with a p-value of 0.031. Secondary endpoints, including Forced Vital Capacity (FVC) and CT gas trapping, also showed significant improvements with p-values of 0.031 and 0.048, respectively. Patients with higher baseline Forced Expiratory Volume (FEV1) experienced a notable 6.4% increase in FEV1 and those with milder disease also saw benefits, particularly in small airway disease markers like the Lung Clearance Index (LCI) (Altonet al., 2015; Altonet al., 2016).

A Phase II multicenter, double-blind, placebo-controlled study investigated the efficacy and safety of CFTR gene transfer using the tgAAVCF vector in patients with cystic fibrosis. The study focused on comparing the rate of recurrent sinusitis between tgAAVCF-treated and placebo-treated sinuses, using each patient as their own control. The results showed no significant differences in the levels of the pro-inflammatory cytokine IL-8 in both short-term (p=0.1155) and long-term (p=0.1653) analyses. However, there was a significant increase in the anti-inflammatory cytokine IL-10 over time (p=0.0261), suggesting that the delivery of the CFTR gene may have helped reduce inflammation in patients (Wagneret al., 2002).

The Roll-Over Study of Ivacaftor in children with cystic fibrosis under 6 years of age, who have a CFTR gating mutation, examined the effects of ivacaftor over 84 weeks with age- and weight-based dosing. The study found that ivacaftor was well tolerated in children aged 2 to 5, with sustained improvements in sweat chloride levels, weight, Body Mass Index (BMI) z-scores and fecal elastase-1 over the extended treatment period. However, 30% of the children developed elevated transaminase levels, indicating potential liver enzyme abnormalities. Despite this, the overall benefits of ivacaftor in this pediatric population were maintained throughout the study (Rosenfeldet al., 2019).

Despite advancements in cystic fibrosis treatment, there are still issues that affect patients’ quality of life and treatment effectiveness. Current treatments focus on symptom management rather than treating the underlying genetic issue, leading to thick, sticky mucus. CFTR modulators have limited efficacy, with 10% of patients not benefiting. High costs make them unaffordable, particularly in low- and middle-income countries. Antibiotic resistance is another major issue and lengthy treatment plans affect patients’ quality of life and adherence to treatment (Burgener and Moss, 2018; Altabeeet al., 2022).

Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) treatment is promising due to advancements in gene editing, medication and personalized care. CFTR modulators, like ivacaftor, lumacaftor and elexacaftor, have improved lung function and quality of life for many patients. Research aims to develop next-generation modulators with increased efficacy. Gene editing technologies, like CRISPR-Cas9, offer a long-term cure by directly repairing the faulty CFTR gene in patient cells. Clinical trials are ongoing to investigate the safety and effectiveness of these strategies. Stem cell therapy is also being explored to repair healthy lung tissue. Personalized medicine, which uses patient-specific data to customize medications, is a growing trend in medicine. Combining these approaches could significantly improve cystic fibrosis patients’ quality of life and shift the focus of CFTR therapy from symptom relief to a permanent cure. Collaboration between researchers, physicians and the pharmaceutical industry is crucial for advancing these treatments (Abdelnour, Xie, Hassanin, Zuo, and Lu, 2021; Kramer and Clancy, 2016).

Despite significant advancements in cystic fibrosis treatment through CFTR modulators, major challenges remain. Current therapies are non-responsive to many mutations, leaving a significant portion of the CF population without effective treatment options. Genetic therapy faces practical obstacles like high costs, efficiency issues and risk of off-target effects. Limited long-term safety and efficacy data, delivery difficulties and ethical concerns complicate its application. To overcome these limitations, next-generation gene modulators must target non-responsive mutations, stem cell therapy and one-time treatment options like genetic modifications.

I would like to express my sincere gratitude to the research community whose invaluable contributions on cystic fibrosis cited for this review article.